Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:
”Do all leukoreduction filters perform the same? Not really…
In transfusion medicine, not all filters are equal. Behind what looks like a simple device lie technical choices that directly impact patient safety and blood product quality. So… how do you know which one is the right filter?
Here are the 4 key criteria:
Leukoreduction performance
• European standard: ≤ 1 million residual white blood cells
• AABB standard: ≤ 5 million
In practice, users often expect a filter to perform 5 to 10 times better than these limits, to ensure stability and safety.
Residual losses
An efficient filter retains leukocytes… but it may also trap red blood cells. Too much loss = a direct impact on hemoglobin levels, or on the required minimum recovery (≥ 85% according to AABB). The challenge is to find the right balance.
Filtration speed
Some centers want ultra-fast processing. Others prefer quality over speed. It all depends on the number of units to process daily and the available “masked time.”
Final component quality
Filters also influence hemolysis in red blood cells or platelet activation in PC. An invisible variable… but one that determines therapeutic value.
Conclusion – there is no such thing as a “perfect” filter. The right filter is the one that fits your process, your priorities, and your patients.
And you, which of these criteria weighs the most in your decisions?”
Stay updated on the emerging in transfusion medicine with Hemostasis Today.
-
Sep 5, 2025, 14:06Thrombosis Update: VTE Death Rate 3X Higher in Los Angeles Jails Than General Population
-
Sep 4, 2025, 22:00Shivani Modi Highlights SOHO 2025 Study Linking Elevated WBC Counts to Increased Thrombosis Risk
-
Sep 4, 2025, 22:00Cancer, Clots and Communication: Register Now for The Upcoming Webinar on CAT!
-
Sep 4, 2025, 11:52PARTHENOPE Trial: A New Benchmark in Risk Score Validation
-
Sep 4, 2025, 09:46SOHO 2025: Exploring AI in Hematology and Oncology
-
Sep 5, 2025, 14:04Melasma Treatment Advances: Non-Ablative Laser and Tranexamic Acid Combination Explained
-
Sep 5, 2025, 12:55RENOVE and API-CAT Trials: Exploring Secondary VTE Prevention
-
Sep 5, 2025, 12:18Lucia Masarova Presents Results of Phase III SURPASS-ET Trial at SOHO 2025: Ropeg's Efficacy for Essential Thrombocythemia
-
Sep 5, 2025, 06:28Digital Twin Study Predicts Higher Thrombotic Recurrence with DOACs vs VKAs in APS Patients
-
Sep 4, 2025, 22:00Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 5, 2025, 14:12EAHAD Podcast: Reducing Pain and Distress in Children Receiving Emicizumab
-
Sep 5, 2025, 03:18Pier Mannuccio Mannucci on How Green Spaces and Physical Activity Can Help Prevent Heart Failure
-
Sep 5, 2025, 02:15Abdul Mannan Explains How DOACs Can Confuse Lupus Anticoagulant Testing
-
Sep 4, 2025, 11:55Sumyea Kabir Highlights the Critical Role of Safe Donors in Blood Transfusion Safety
-
Sep 3, 2025, 14:18Living with Factor V Deficiency: Helen’s Inspiring Story on Haemnet Haemcast